GlassScriptPhysician profile
Edwin K Matthews
NPI 1316965908
$14,366.23
in general payments reported to CMS, 2019-2025
50 companies · $1,319 in 2025
The $1,319 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,620 · 2020: $2,031 · 2021: $2,479 · 2022: $2,331 · 2023: $2,468 · 2024: $2,118 · 2025: $1,319.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,844 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,843.64 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,349.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,314.05 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,227.38 | 2021-2025 | |
| Amarin Pharma, INC. | $1,070.38 | 2019-2022 | |
| Lilly USA, LLC | $1,043.15 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $838.39 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $634.26 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $453.43 | 2019-2023 | Synjardy, Jardiance, Tradjenta |
| Amgen INC. | $433.36 | 2019-2025 | Repatha, Otezla, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $405.12 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $397.05 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $293.17 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $286.08 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $272.52 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $249.12 | 2019-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.